Tianjin Tianyao Pharmaceuticals (600488.SH) subsidiary receives registration certificate for Butorphanol Tartrate Injection.

Tianjin Tianyao Pharmaceuticals (600488.SH) announced that its subsidiary, Jin Medicine He Ping (Tianjin) Pharmaceutical Co., Ltd. (referred to as "Jin Medicine He Ping"), has received the "Drug Registration Certificate" for the approved issuance of tartaric acid butorphanol injection by the State Food and Drug Administration. The main component of tartaric acid butorphanol injection is tartaric acid butorphanol, which belongs to the second category of psychotropic drugs stipulated in the National Regulations on the Administration of Anesthetic and Psychotropic Drugs, indicated for the treatment of various cancer-related pain and postoperative pain. In October 2023, Jin Medicine He Ping submitted the application for domestic production drug registration and market approval to the National Medical Products Administration Drug Evaluation Center and was accepted. In October 2025, it obtained the drug registration certificate issued by the National Medical Products Administration. Up to now, Jin Medicine He Ping has accumulated research and development expenses of over 22 million yuan on the tartaric acid butorphanol injection project.